首页> 外文期刊>The journal of clinical endocrinology and metabolism >PVALB, a New Hu?rthle Adenoma Diagnostic Marker Identified through Gene Expression
【24h】

PVALB, a New Hu?rthle Adenoma Diagnostic Marker Identified through Gene Expression

机译:PVALB,一种通过基因表达鉴定的新的人类腺瘤诊断标志物

获取原文
       

摘要

Context: A better means to accurately identify malignant thyroid nodules and to distinguish them from benign tumors is needed. We previously identified markers for detecting thyroid malignancy, with sensitivity estimated at or close to 100%. One lingering problem with these markers was that false positives occurred with Hu?rthle cell adenomas (HCA) which lowered test specificity.Methods: To locate accurate diagnostic markers, we profiled in depth the transcripts of a HCA and a Hu?rthle cell carcinoma (HCC). From 1146 differentially expressed genes, 18 transcripts specifically expressed in HCA were tested by quantitative PCR in a wide range of thyroid tumors (n = 76). Sensibility and specificity were calculated using receiver operating characteristic (ROC). Selected markers were further validated in an independent set of thyroid tumors (n = 82) by immunohistochemistry. To define the panel that would yield best diagnostic accuracy, these markers were tested in combination with our previous identified markers.Results: Seventeen of the 18 genes showed statistical significance based on a mean relative level of expression ( P < 0.05). KLK1 (sensitivity = 0.97) and PVALB (sensitivity = 0.94) were the best candidate markers. The combination of PVALB and C1orf24 increased specificity to >97% and maintained sensitivity for detection of carcinoma.Conclusion: We identified tumor markers that can be used in combination for a more accurate preoperative diagnosis of thyroid nodules and for postoperative diagnosis of thyroid carcinoma in tumor sections. This improved test would help physicians rapidly focus treatment on true malignancies and avoid unnecessary treatment of benign tumors, simultaneously improving medical care and reducing costs.
机译:背景:需要一种更好的方法来准确识别甲状腺恶性结节并将其与良性肿瘤区分开。我们先前确定了检测甲状腺恶性肿瘤的标志物,其敏感性估计为或接近100%。这些标记物的一个挥之不去的问题是,Huthrth细胞腺瘤(HCA)发生了假阳性,从而降低了测试的特异性。 HCC)。从1146个差异表达基因中,通过定量PCR在广泛的甲状腺肿瘤(n = 76)中检测了在HCA中特异性表达的18个转录物。敏感性和特异性使用受体工作特征(ROC)计算。通过免疫组织化学进一步在一组独立的甲状腺肿瘤(n = 82)中验证所选标记。为了确定将产生最佳诊断准确度的面板,将这些标记物与我们先前鉴定的标记物一起进行了测试。结果:18个基因中有17个显示了基于平均相对表达水平的统计学意义(P <0.05)。 KLK1(敏感性= 0.97)和PVALB(敏感性= 0.94)是最佳候选标记。 PVALB和C1orf24的组合可将特异性提高至> 97%,并保持检测癌症的敏感性。结论:我们确定了可结合使用的肿瘤标志物,可更准确地对甲状腺结节进行术前诊断和对肿瘤中的甲状腺癌进行术后诊断部分。这项经过改进的测试将帮助医生迅速将治疗重点放在真正的恶性肿瘤上,避免对良性肿瘤进行不必要的治疗,同时改善医疗质量并降低成本。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号